These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2576924)

  • 41. Evidence for direct action of estradiol on growth hormone-releasing factor (GRF) in rat hypothalamus: localization of [3H]estradiol in GRF neurons.
    Shirasu K; Stumpf WE; Sar M
    Endocrinology; 1990 Jul; 127(1):344-9. PubMed ID: 1972921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide, and somatostatin on the release of thyrotropin from the bullfrog pituitary.
    Okada R; Yamamoto K; Ito Y; Chartrel N; Leprince J; Fournier A; Vaudry H; Kikuyama S
    Ann N Y Acad Sci; 2006 Jul; 1070():474-80. PubMed ID: 16888212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [In vitro study of the interaction between neuromediators and neuropeptides involved in hypothalamic neurosecretion control (author's transl)].
    Epelbaum J; Drouva SV; Tapioa-Arancibia L; Laplante E; Kordon C
    Ann Endocrinol (Paris); 1980; 41(6):478-86. PubMed ID: 6113815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.
    Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL
    Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Presynaptic modulation by VIP, secretin and isoproterenol of somatostatin release from enriched enteric synaptosomes: role of cAMP.
    Kurjak M; Schusdziarra V; Allescher HD
    Eur J Pharmacol; 1996 Oct; 314(1-2):165-73. PubMed ID: 8957233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroendocrine significance of vasoactive intestinal polypeptide.
    Reichlin S
    Ann N Y Acad Sci; 1988; 527():431-49. PubMed ID: 2898911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diurnal variation in the effect of potassium depolarization on vasoactive intestinal polypeptide release from rat hypothalamus: a possible role for adrenaline.
    Burns G; Brown BL; Dobson PR
    J Endocrinol; 1988 Mar; 116(3):335-41. PubMed ID: 3127518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of vasoactive intestinal polypeptide and somatostatin on secretion of epidermal growth factor and bicarbonate from Brunner's glands.
    Kirkegaard P; Olsen PS; Nexø E; Holst JJ; Poulsen SS
    Gut; 1984 Nov; 25(11):1225-9. PubMed ID: 6149978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of vasoactive intestinal polypeptide on gastric acid secretion is predominantly mediated by somatostatin.
    Schubert ML
    Gastroenterology; 1991 May; 100(5 Pt 1):1195-200. PubMed ID: 1672856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vasoactive intestinal peptide secretion by turkey hypothalamic explants.
    Chaiseha Y; Youngren OM; El Halawani ME
    Biol Reprod; 1998 Sep; 59(3):670-5. PubMed ID: 9716568
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of diabetes on in vivo and in vitro hypothalamic somatostatin release.
    Joanny P; Peyre G; Steinberg J; Guillaume V; Pesce G; Becquet D; Oliver C
    Neuroendocrinology; 1992 May; 55(5):485-91. PubMed ID: 1350065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Somatostatin inhibition of VIP- and isoproterenol-stimulated cyclic AMP production in rat peritoneal macrophages.
    Segura JJ; Guerrero JM; Goberna R; Calvo JR
    Neuropeptides; 1992 Sep; 23(1):39-43. PubMed ID: 1357581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vasoactive intestinal peptide affects the GABAergic system in the hypothalamic-pituitary axis.
    Duvilanski BH; Lasaga M; Seilicovich A; Afione S; Díaz MC; Debeljuk L
    Brain Res Bull; 1990 Aug; 25(2):215-9. PubMed ID: 2224536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vasoactive intestinal polypeptide stimulates cholecystokinin secretion in perfused rat duodenum.
    Funakoshi A; Nakano I; Miyazaki K
    Tohoku J Exp Med; 1989 Jan; 157(1):55-9. PubMed ID: 2711376
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Somatostatin inhibits in vitro release of luteinizing hormone releasing hormone from rat mediobasal hypothalamic slices.
    Rotsztejn WH; Drouva SV; Epelbaum J; Kordon C
    Experientia; 1982 Aug; 38(8):974-5. PubMed ID: 6182021
    [No Abstract]   [Full Text] [Related]  

  • 57. Anticonvulsants inhibit rat neuronal somatostatin release.
    Richardson SB; Twente S
    Brain Res; 1992 Feb; 571(2):230-4. PubMed ID: 1351779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vasoactive intestinal peptide-stimulated glycoconjugate secretion from conjunctival goblet cells.
    Dartt DA; Kessler TL; Chung EH; Zieske JD
    Exp Eye Res; 1996 Jul; 63(1):27-34. PubMed ID: 8983961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of intraventricular administration of vasoactive intestinal polypeptide on body temperature in the rat.
    Itoh S; Hirota R
    Jpn J Physiol; 1982; 32(4):677-81. PubMed ID: 6129338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Somatostatin inhibition of VIP-induced somatostatin release, cyclic AMP accumulation and 45Ca2+ uptake in diencephalic cells.
    Pares-Herbute N; Diaz J; Astier H; Tapia-Arancibia L
    Eur J Pharmacol; 1989 Feb; 161(2-3):241-4. PubMed ID: 2566490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.